연골 변성 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

The global demand for Cartilage Degeneration Market is presumed to reach the market size of nearly USD 24.53 Billion by 2032 from USD 12.06 Billion in 2023 with a CAGR of 8.21% under the study period 2024-2032.

Cartilage degeneration refers to the gradual deterioration of cartilage tissue, which cushions between the bones in joints, leading to pain, stiffness, and loss of joint function. It is commonly associated with aging, wear and tear, repetitive stress, or joint injury, such as osteoarthritis. It can result in reduced joint mobility, inflammation, and the development of bone spurs. It may affect joints, including the knees, hips, spine, and hands, causing significant pain and disability. Treatment options for this degeneration include medications, lifestyle modifications, physical therapy, and, in severe instances, surgical interventions such as joint replacement or cartilage repair procedures.

MARKET DYNAMICS

The aging population and the proliferating prevalence of age-related joint diseases such as osteoarthritis drive the demand for innovative treatments and therapies to prevent or slow down cartilage degeneration and improve joint function. Additionally, sports injuries and trauma-related joint damage contribute to the rise in cartilage degeneration cases, particularly among younger and active individuals, driving demand for regenerative medicine approaches and surgical interventions to repair and regenerate damaged cartilage tissue. Moreover, advancements in medical imaging technologies such as MRI and CT scans enable early detection and diagnosis of cartilage degeneration, allowing for timely intervention and treatment to preserve joint function and mobility. Furthermore, the growing investment in research and development by biotechnology companies and academic institutions drives innovation in cartilage repair and regeneration therapies, including tissue engineering, stem cell therapy, and growth factor-based treatments. The escalating focus on patient-centered care & value-based healthcare models drives demand for cost-effective and minimally invasive treatments, promoting conservative management strategies such as weight management, physical therapy, and lifestyle modifications alongside surgical interventions and pharmacological therapies. However, advancements in regenerative medicine and alternative treatment options may challenge the market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Cartilage Degeneration. The growth and trends of Cartilage Degeneration industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Cartilage Degeneration market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Procedure Type

• Joint Replacements
• Chondroplasty
• Osteochondral Transplants
• Microfracture
• Meniscus Transplants
• Cell-based Cartilage Resurfacing
• Autologous Chondrocyte Implantation
• Others

By Application

• Knee
• Hip
• Others

By Treatment Delivery Channel

• Hospitals
• Academic & Research Institutes
• Specialty Clinics
• Ambulatory Surgical Centers
• Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Cartilage Degeneration market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Cartilage Degeneration market include Zimmer Biomet Holdings Inc., Stryker Corporation, Smith & Nephew Plc, B. Braun, Medtronic Plc, Johnson & Johnson (DePuy Synthes), Osiris Therapeutics Inc., Vericel Corporation, Anika Therapeutics Inc., Medipost Co. Ltd., Conmed Corporation, Arthrex Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. CARTILAGE DEGENERATION - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Procedure Type
  • 3.7.2 Market Attractiveness Analysis By Application
  • 3.7.3 Market Attractiveness Analysis By Treatment Delivery Channel
  • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL CARTILAGE DEGENERATION MARKET ANALYSIS BY PROCEDURE TYPE

• 5.1. Overview By Procedure Type
• 5.2. Historical and Forecast Data
• 5.3. Analysis By Procedure Type
• 5.4. Joint Replacements Historic and Forecast Sales By Regions
• 5.5. Chondroplasty Historic and Forecast Sales By Regions
• 5.6. Osteochondral Transplants Historic and Forecast Sales By Regions
• 5.7. Microfracture Historic and Forecast Sales By Regions
• 5.8. Meniscus Transplants Historic and Forecast Sales By Regions
• 5.9. Cell-based Cartilage Resurfacing Historic and Forecast Sales By Regions
• 5.10. Autologous Chondrocyte Implantation Historic and Forecast Sales By Regions
• 5.11. Others Historic and Forecast Sales By Regions

6. GLOBAL CARTILAGE DEGENERATION MARKET ANALYSIS BY APPLICATION

• 6.1. Overview By Application
• 6.2. Historical and Forecast Data
• 6.3. Analysis By Application
• 6.4. Knee Historic and Forecast Sales By Regions
• 6.5. Hip Historic and Forecast Sales By Regions
• 6.6. Others Historic and Forecast Sales By Regions

7. GLOBAL CARTILAGE DEGENERATION MARKET ANALYSIS BY TREATMENT DELIVERY CHANNEL

• 7.1. Overview By Treatment Delivery Channel
• 7.2. Historical and Forecast Data
• 7.3. Analysis By Treatment Delivery Channel
• 7.4. Hospitals Historic and Forecast Sales By Regions
• 7.5. Academic & Research Institutes Historic and Forecast Sales By Regions
• 7.6. Specialty Clinics Historic and Forecast Sales By Regions
• 7.7. Ambulatory Surgical Centers Historic and Forecast Sales By Regions
• 7.8. Others Historic and Forecast Sales By Regions

8. GLOBAL CARTILAGE DEGENERATION MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2 North America By Segment Sales Analysis
  • 8.3.3 North America By Country Sales Analysis
  • 8.3.4 United States Sales Analysis
  • 8.3.5 Canada Sales Analysis
  • 8.3.6 Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2 Europe By Segment Sales Analysis
  • 8.4.3 Europe By Country Sales Analysis
  • 8.4.4 United Kingdom Sales Analysis
  • 8.4.5 France Sales Analysis
  • 8.4.6 Germany Sales Analysis
  • 8.4.7 Italy Sales Analysis
  • 8.4.8 Russia Sales Analysis
  • 8.4.9 Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2 Asia Pacific By Segment Sales Analysis
  • 8.5.3 Asia Pacific By Country Sales Analysis
  • 8.5.4 China Sales Analysis
  • 8.5.5 India Sales Analysis
  • 8.5.6 Japan Sales Analysis
  • 8.5.7 South Korea Sales Analysis
  • 8.5.8 Australia Sales Analysis
  • 8.5.9 South East Asia Sales Analysis
  • 8.5.10 Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2 Latin America By Segment Sales Analysis
  • 8.6.3 Latin America By Country Sales Analysis
  • 8.6.4 Brazil Sales Analysis
  • 8.6.5 Argentina Sales Analysis
  • 8.6.6 Peru Sales Analysis
  • 8.6.7 Chile Sales Analysis
  • 8.6.8 Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2 Middle East & Africa By Segment Sales Analysis
  • 8.7.3 Middle East & Africa By Country Sales Analysis
  • 8.7.4 Saudi Arabia Sales Analysis
  • 8.7.5 UAE Sales Analysis
  • 8.7.6 Israel Sales Analysis
  • 8.7.7 South Africa Sales Analysis
  • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE CARTILAGE DEGENERATION COMPANIES

• 9.1. Cartilage Degeneration Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10. COMPANY PROFILES OF CARTILAGE DEGENERATION INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Market Concentration Rate
• 10.3. Zimmer Biomet Holdings Inc.
  • 10.3.1 Company Overview
  • 10.3.2 Company Revenue
  • 10.3.3 Products
  • 10.3.4 Recent Developments
• 10.4. Stryker Corporation
  • 10.4.1 Company Overview
  • 10.4.2 Company Revenue
  • 10.4.3 Products
  • 10.4.4 Recent Developments
• 10.5. Smith & Nephew Plc
  • 10.5.1 Company Overview
  • 10.5.2 Company Revenue
  • 10.5.3 Products
  • 10.5.4 Recent Developments
• 10.6. B. Braun
  • 10.6.1 Company Overview
  • 10.6.2 Company Revenue
  • 10.6.3 Products
  • 10.6.4 Recent Developments
• 10.7. Medtronic Plc
  • 10.7.1 Company Overview
  • 10.7.2 Company Revenue
  • 10.7.3 Products
  • 10.7.4 Recent Developments
• 10.8. Johnson & Johnson (DePuy Synthes)
  • 10.8.1 Company Overview
  • 10.8.2 Company Revenue
  • 10.8.3 Products
  • 10.8.4 Recent Developments
• 10.9. Osiris Therapeutics Inc.
  • 10.9.1 Company Overview
  • 10.9.2 Company Revenue
  • 10.9.3 Products
  • 10.9.4 Recent Developments
• 10.10. Vericel Corporation
  • 10.10.1 Company Overview
  • 10.10.2 Company Revenue
  • 10.10.3 Products
  • 10.10.4 Recent Developments
• 10.11. Anika Therapeutics Inc.
  • 10.11.1 Company Overview
  • 10.11.2 Company Revenue
  • 10.11.3 Products
  • 10.11.4 Recent Developments
• 10.12. Medipost Co. Ltd.
  • 10.12.1 Company Overview
  • 10.12.2 Company Revenue
  • 10.12.3 Products
  • 10.12.4 Recent Developments
• 10.13. Conmed Corporation
  • 10.13.1 Company Overview
  • 10.13.2 Company Revenue
  • 10.13.3 Products
  • 10.13.4 Recent Developments
• 10.14. Arthrex Inc
  • 10.14.1 Company Overview
  • 10.14.2 Company Revenue
  • 10.14.3 Products
  • 10.14.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies